
Precision immunological diagnostics will be a future mainstay in everyday at home and in office testing. Biotome has created novel linear epitopes to assess stomach cancer risk (Helitope®) and SARS-CoV-2 infection (Covitope®). In an effort to provide rapid, at-home testing for stomach cancer and other disease states, Cardea and Biotome have entered into a technology development partnership to usher this product to market. As Biotome’s epitope discovery platform is agnostic, the partnership sets the groundwork to provide tests to consumers in all facets of human health and wellness.